The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region

被引:181
作者
Barnet, SW
Lu, S
Srivastava, I
Cherpelis, S
Gettie, A
Blanchard, J
Wang, S
Mboudjeka, I
Leung, L
Lian, Y
Fong, A
Buckner, C
Ly, A
Hilt, S
Ulmer, J
Wild, CT
Mascola, JR
Stamatatos, L
机构
[1] Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA
[2] Chiron Corp, Emeryville, CA 94608 USA
[3] Tulane Reg Primate Res Ctr, Covington, LA 70433 USA
[4] Panacos Pharmaceut, Gaithersburg, MD 20877 USA
[5] Walter Reed Army Inst Res, Rockville, MD 20850 USA
[6] Univ Massachusetts, Med Ctr, Worcester, MA 01655 USA
关键词
D O I
10.1128/JVI.75.12.5526-5540.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Partial deletion of the second hypervariable region from the envelope of the primary-like SF162 virus increases the exposure of certain neutralization epitopes and renders the virus, SF162 Delta V2, highly susceptible to neutralization by clade B and non-clade B human immunodeficiency virus (HIV-positive) sera (L, Stamatatos and C, Cheng-Mayer, J, Virol, 78:7840-7845, 1998), This observation led us to propose that the modified, SF162 Delta V2-derived envelope may elicit higher titers of cross-reactive neutralizing antibodies than the unmodified SF162-derived envelope. To test this hypothesis, we immunized rabbits and rhesus macaques with the gp140 form of these two envelopes, In rabbits, both immunogens elicited similar titers of binding antibodies but the modified immunogen was more effective in eliciting neutralizing antibodies, not only against the SF162 Delta V2 and SF162 viruses but also against several heterologous primary HIV type 1 (HIV-1) isolates. In rhesus macaques both immunogens elicited potent binding antibodies, but again the modified immunogen was more effective in eliciting the generation of neutralizing antibodies against the SF162 Delta V2 and SF162 viruses, Antibodies capable of neutralizing several, but not all, heterologous primary HIV-1 isolates tested were elicited only in macaques immunized with the modified immunogen, The efficiency of neutralization of these heterologous isolates was lower than that recorded against the SF162 isolate, Our results strongly suggest that although soluble oligomeric envelope subunit vaccines may elicit neutralizing antibody responses against heterologous primary HIV-1 isolates, these responses will not be broad and potent unless specific modifications are introduced to increase the exposure of conserved neutralization epitopes.
引用
收藏
页码:5526 / 5540
页数:15
相关论文
共 43 条
[1]   CRYPTIC NATURE OF ENVELOPE V3 REGION EPITOPES PROTECTS PRIMARY MONOCYTOTROPIC HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 FROM ANTIBODY NEUTRALIZATION [J].
BOUHABIB, DC ;
RODERIQUEZ, G ;
ORAVECZ, T ;
BERMAN, PW ;
LUSSO, P ;
NORCROSS, MA .
JOURNAL OF VIROLOGY, 1994, 68 (09) :6006-6013
[2]   Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1 [J].
Bures, R ;
Gaitan, A ;
Zhu, TF ;
Graziosi, C ;
McGrath, KM ;
Tartaglia, J ;
Caudrelier, P ;
EL Habib, R ;
Klein, M ;
Lazzarin, A ;
Stablein, DM ;
Deers, M ;
Corey, L ;
Greenberg, ML ;
Schwartz, DH ;
Montefiori, DC .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (18) :2019-2035
[3]   Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein [J].
Cao, J ;
Sullivan, N ;
Desjardin, E ;
Parolin, C ;
Robinson, J ;
Wyatt, R ;
Sodroski, J .
JOURNAL OF VIROLOGY, 1997, 71 (12) :9808-9812
[4]   EFFECT OF INTRON-A FROM HUMAN CYTOMEGALOVIRUS (TOWNE) IMMEDIATE-EARLY GENE ON HETEROLOGOUS EXPRESSION IN MAMMALIAN-CELLS [J].
CHAPMAN, BS ;
THAYER, RM ;
VINCENT, KA ;
HAIGWOOD, NL .
NUCLEIC ACIDS RESEARCH, 1991, 19 (14) :3979-3986
[5]   VIRAL DETERMINANTS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 T-CELL OR MACROPHAGE TROPISM, CYTOPATHOGENICITY, AND CD4 ANTIGEN MODULATION [J].
CHENGMAYER, C ;
QUIROGA, M ;
TUNG, JW ;
DINA, D ;
LEVY, JA .
JOURNAL OF VIROLOGY, 1990, 64 (09) :4390-4398
[6]   DNA vaccination with the human immunodeficiency virus type 1 SF162ΔV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8+ T-cell-depleted rhesus macaques [J].
Cherpelis, S ;
Shrivastava, I ;
Gettie, A ;
Jin, X ;
Ho, DD ;
Barnett, SW ;
Stamatatos, L .
JOURNAL OF VIROLOGY, 2001, 75 (03) :1547-1550
[7]   NEUTRALIZATION OF PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ISOLATES BY THE BROADLY REACTIVE ANTI-V3 MONOCLONAL-ANTIBODY, 447-52D [J].
CONLEY, AJ ;
GORNY, MK ;
KESSLER, JA ;
BOOTS, LJ ;
OSSORIOCASTRO, M ;
KOENIG, S ;
LINEBERGER, DW ;
EMINI, EA ;
WILLIAMS, C ;
ZOLLAPAZNER, S .
JOURNAL OF VIROLOGY, 1994, 68 (11) :6994-7000
[8]   Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: Performance criteria for selecting candidate antibodies for clinical trials [J].
DSouza, MP ;
Livnat, D ;
Bradac, JA ;
Bridges, SH ;
Bryson, Y ;
Hanson, C ;
Matthews, T ;
Moore, J ;
Trkola, A ;
ZollaPazner, S ;
Gorny, M ;
Burton, D ;
Merigan, T ;
McNamara, J ;
Norcross, M ;
Posner, M ;
Robinson, J ;
ViraniKetter, N ;
Barbas, CF ;
Parren, P ;
Katinger, H .
JOURNAL OF INFECTIOUS DISEASES, 1997, 175 (05) :1056-1062
[9]   MUTATIONAL ANALYSIS OF THE ASSEMBLY DOMAIN OF THE HIV-1 ENVELOPE GLYCOPROTEIN [J].
EARL, PL ;
MOSS, B .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1993, 9 (07) :589-594
[10]   BIOLOGICAL AND IMMUNOLOGICAL PROPERTIES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE GLYCOPROTEIN - ANALYSIS OF PROTEINS WITH TRUNCATIONS AND DELETIONS EXPRESSED BY RECOMBINANT VACCINIA VIRUSES [J].
EARL, PL ;
KOENIG, S ;
MOSS, B .
JOURNAL OF VIROLOGY, 1991, 65 (01) :31-41